Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer withFGFR1amplification: A single-arm, phase 2 study
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer withFGFR1amplification: A single-arm, phase 2 study
Authors
Keywords
-
Journal
CANCER
Volume 122, Issue 19, Pages 3024-3031
Publisher
Wiley
Online
2016-06-18
DOI
10.1002/cncr.30135
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers
- (2015) F. Goke et al. CLINICAL CANCER RESEARCH
- Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
- (2015) D. R. Gandara et al. CLINICAL CANCER RESEARCH
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer
- (2015) Sun Min Lim et al. EUROPEAN JOURNAL OF CANCER
- Second-line dovitinib in metastatic endometrial cancer
- (2015) Matthew S Block et al. LANCET ONCOLOGY
- The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer
- (2015) Ji Soo Park et al. LUNG CANCER
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
- (2014) B. Besse et al. ANNALS OF ONCOLOGY
- Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
- (2014) B. Escudier et al. CLINICAL CANCER RESEARCH
- FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
- (2014) M. W. Wynes et al. CLINICAL CANCER RESEARCH
- Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
- (2014) Matthew I. Milowsky et al. EUROPEAN JOURNAL OF CANCER
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
- (2013) E. Angevin et al. CLINICAL CANCER RESEARCH
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- (2013) F. Andre et al. CLINICAL CANCER RESEARCH
- Prognostic Value of Fibroblast Growth Factor Receptor 1 Gene Locus Amplification in Resected Lung Squamous Cell Carcinoma
- (2013) Kenneth J. Craddock et al. Journal of Thoracic Oncology
- Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck
- (2013) Friederike Göke et al. MODERN PATHOLOGY
- Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer
- (2013) Anne M Schultheis et al. MODERN PATHOLOGY
- Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities
- (2012) P. Perez-Moreno et al. CLINICAL CANCER RESEARCH
- Nectin-1 Binds and Signals through the Fibroblast Growth Factor Receptor
- (2012) Kirsten B. Bojesen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer
- (2012) Hye Ryun Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer
- (2012) Hans-Ulrich Schildhaus et al. MODERN PATHOLOGY
- Pathology of Lung Cancer
- (2011) William D. Travis CLINICS IN CHEST MEDICINE
- Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
- (2011) Amit Dutt et al. PLoS One
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started